IFNα-2b is clinically approved to treat chronic hepatitis B, hairy cell leukemia, malignant melanoma, follicular lymphoma, and chronic and acute hepatitis C. IFNα has also been utilized in the treatment of other cancer types. This evidence concerns the gene IFNA2 and hepatitis C virus infection.